Home Up Feedback Contents Search Sell your Prod. Meet us News           

 
Home • Up

H-FABP ELISA

 

Home

GENTAUR

+32 1658 9045

or

0032 (0)16 41 44 07

+32 1650 9045

[email protected]

Av. de l' Armée 68

B-1040 Brussels

BELGIUM

France

tel 01 43 25 01 50

fax01 43 25 01 60

9, rue Lagrange

75005 Paris

Italia

tel 02 36 00 65 93

fax 02 36 00 65 94

20135 Milano

Deutschland

tel +32 1658 9045

fax +32 1650 9045

Polska

Tel 058 710 33 44

Fax 00 32 16 50 90 45

ul. Grunwaldzka 88A/2

81-771 Sopot

日本

tel +81 78 386 0860

fax +81 78 306 0296

Minaatojimaminami-manchi

Chuo-ku, Kobe

065-0047

Österreich
+43720880899

Canada Montreal
+15149077481

Česká republika Praha
+420246019719

Danmark
+4569918806

Finland Helsset
+358942419041

Ελλάς Αθήνα
+302111768494

Magyarország Budapest
+3619980547

Ireland Dublin
+35316526556

Luxembourg
+35220880274

Nederland
+31208080893

Norge Oslo
+4721031366

Polska Warszawa
+48223988221

Sverige Stockholm
+46852503438

Schweiz Züri
+41435006251

US New York
+17185132983

Other Countries
0032 (0)16 41 44 07


 

 

 

 

 

Reagent for quantification of heart-type fatty acid-binding protein (H-FABP) in serum and plasma

For research use only

MARKIT-M H-FABP ELISA

 

 

 

Heart-type fatty acid-binding protein (H-FABP) is

a soluble cytoplasmic protein with a low molecular weight of 14.9 kDa which is present           abundantly in the myocardium. When the myocardium is injured, H-FABP is easily released into the circulation even if in superacute phase within 3 hrs after the onset of symptoms. Therefore, H-FABP is thought to be an exellent biomarker for the diagnosis of acute myocardial infarction. MARKIT-M H-FABP is a direct sandwich enzyme-linked immunosorbent assay (ELISA) for the quantification of H-FABP in human serum and plasma using two distinct anti-human H-FABP monoclonal antibodies.

Application

Quantification of H-FABP in human serum and plasma

Assay procedure for MARKIT-M H-FABP


Contents of MARKIT-M H-FABP

Each kit (96 tests) contains the following reagents.

Standard 0 (lyophilized): 1 vial (for2.0 mL).

Standard 5 (lyophilized): 1 vial (for 0.5 mL) contains 2.5 ng of H-FABP*.

Standard 10 (lyophilized): 1 vial (for 0.5 mL) contains 5 ng of H-FABP*.

Standard 25 (lyophilized): 1 vial (for 0.5 mL) contains 12.5 ng of H-FABP*.

Standard 50 (lyophilized): 1 vial (for 0.5 mL) contains 25 ng of H-FABP*.

Standard 100 (lyophilized): 1 vial (for 0.5 mL) contains 50 ng of H-FABP*.

Standard 250 (lyophilized): 1 vial (for 0.5 mL) contains 125 ng of H-FABP*.

H-FABP antibody-coated wells: 1 plate (96 wells).  Each well contains: anti-human H-FABP monoclonal antibody.

Buffer solution (bottle No. 1): 1 bottle (10 mL).

Wash buffer concentrate (bottle No. 2): 3 bottles (30 mL each).

H-FABP antibody-enzyme conjugate (bottle No. 3): 1 bottle (15 mL), containing HRP-labeled anti-human H-FABP monoclonal antibody.

Substrate tablets: 3.  Each tablet contains o-phenylenediamine dihydrochloride (OPD) (13 mg).

Substrate diluent buffer (bottle No. 4): 3 bottles (15 mL each). Each bottle contains hydrogen peroxide (15μL).

Stop solution (bottle No. 5): 1 bottle (15 mL).

Microplate for dilution: 1 plate (96 wells).

Graph paper: 3 sheets.

*H-FABP: Human H-FABP is quantitatively determined by an immunological method using purified human H-FABP as a standard material.

Performance

1. Reproducibility

When two distinct samples (H-FABP, 50-200 ng/mL) are determined 10 times simultaneously, the coefficient of variation in their absorbances should be less than 10 %.

2. Assay range

H-FABP 1.25 -250 ng/mL

 

Cut-off level of H-FABP

A mass concentration of 6.2 ng of H-FABP per mL of serum or plasma is designated as the cut-off value for the diagnosis of acute myocardial infarction.  For clinical assessment this value shows the highest diagnostic efficacy.  An H-FABP mass concentration of 6.2 ng/mL of serum or plasma or higher is strongly suggestive of cardiac damage.

Storage method and expiry period

Storage: Store in a cool place (2-10oC), protected from light.  Avoid freezing.

Expiry period: 2 years

References

1) Ockner, R.K., et al.: Mol. Cell. Biochem. 98: 3-9, 1990.

2) Kaikaus, R.M., et al.: Experientia 46: 617-630, 1990.

3) Ohkaru, Y., et al.: J. Immunol. Methods 178: 99-111, 1995.

4) Tsuji, R., et al.: Int. J. Cardiol. 41: 209-217, 1993.

5) Sohmiya, K., et al.: J. Mol. Cell. Cardiol. 25: 1413-1426, 1993.

6) Tanaka, T., et al.: Clin. Biochem. 24: 195-201, 1991.

7) Paulussen, R.J.A., et al.: Int. J. Biochem. 22: 393-398, 1990.

8) Adams, J.E. III, et al.: Circulation 88: 750-763, 1993.

9) Pauleo, P.R. and Roberts, R.: Cardiol. Clin. 6: 97-109, 1988.

10) Veerkamp, J.H., et al.: Prog. Lipid Res. 34: 17-52, 1995.

11) Glatz, J.F.C., et al.: Br. Heart J. 71: 135-140, 1994.

12) Wodzig, K.W.H., et al.: Eur. J. Clin. Chem. Clin. Biochem. 35: 191-198, 1997.

 

Copyright © 2002 GENTAUR Molecular Products
Last modified: 05/29/09